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Purpose: To investigate the long-term efficacy of 125I brachytherapy in early-stage prostate cancer and to identify
correlating factors.
Methods: This study included 117 cases of early stage prostate cancer. The patients ranged in age from 51 to 84 years,
with a mean of 73 years. The features of the study population were as follows: the PSA ranged from 0.4 to 47.6 ng/ml
(median, 14.7); the Gleason score ranged from 4 to 9 (mean, 6.4); the clinical stage ranged from T1b to T2c; and
the positive biopsy rate ranged from 0.08 to 1.0 (mean, 0.45). The mean D90 was 142 Gy and ranged from 106 Gy
to 170 Gy. The numbers of low-risk, intermediate-risk and high-risk prostate cancer cases were 22, 29 and 66,
respectively. The biochemical no evidence of disease (bNED) rate and overall survival were recorded. Factors that
correlated with the outcomes were evaluated.
Results: With a mean follow up of 84 months, 33 cases had biochemical recurrence, with a bNED rate of 72%.
The overall survival rate was 90%, and the cancer-specific survival rate was 97%. The bNED rates in the low-risk,
intermediate-risk and high-risk groups were 86%, 79% and 64%, respectively (P = 0.040). The patients with
PSA <20 ng/ml, a positive biopsy rate lower than 0.5, and D90≥ 140 Gy had lower biochemical recurrence (P = 0.028,
0.006, 0.009, respectively).
Conclusions: The long-term efficacy of 125I brachytherapy in early stage prostate cancer was shown. bNED is related to
risk stratification, PSA level, positive biopsy rate and D90.
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Brachytherapy is a radical treatment that can achieve the
same effect as radical prostatectomy and external beam
radiotherapy (EBRT) (Nag et al. 1999; Davis et al. 2012;
Park et al. 2013). However, studies of the long-term clin-
ical outcome in large cohorts of prostate cancer patients
treated with brachytherapy from mainland China are lack-
ing. A total of 564 patients with localized prostate cancer
were treated with brachytherapy from December 2003 to
August 2013 in Peking Union Medical College Hospital.
Among the 138 patients who underwent brachytherapy
before December 2007, 117 patients were followed.* Correspondence: ywgemailbox@sina.com
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Patient characteristics
A total of 117 consecutive patients with localized pros-
tate cancer treated with brachytherapy were enrolled in
this retrospective analysis (Table 1). The mean age of the
studied cohort was 73 years, ranging from 51 years to 84
years. All of the patients were diagnosed with prostate
cancer based on transperineal ultrasound-guided pros-
tate biopsy. The mean PSA level was 14.7 ng/ml, ranging
from 0.4 ng/ml to 47.6 ng/ml. The Gleason score ranged
from 4 to 9, with a median of 6. The clinical stage
ranged from T1b to T2c. The mean prostate volume was
31 ml, ranging from 13 ml to 69 ml. The mean percent
positive core (PPC) was 45%, ranging from 8% to 100%.
In each patient, pretreatment CT or MRI of the thorax/Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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vesicle or pelvic lymph node involvement and no distant
metastasis. Patients were clinically staged based on a med-
ical history and physical and imaging examinations.
The risk stratification of the study population complied
with the standard provided by NCCN updated in 2012.
The low-risk subgroup with a PSA ≤ 10.0 ng/ml, a Gleason
score of 2–6 and Stage T1-T2a included 22 patients; 3
patients in this subgroup received neo-adjuvant andro-
gen deprivation therapy (ADT) to shrink prostate before
brachytherapy, but the other 19 patients underwentbrachytherapy alone. The intermediate-risk subgroup
with 10 ng/ml < PSA ≤ 20.0 ng/ml, a Gleason score of 7
and Stage T2b included 29 patients, all of whom under-
went 6 months of ADT after brachytherapy. The high-
risk group was defined as those with PSA ≥20.0 ng/ml, a
Gleason score of 8–10 and Stage T2c. ADT consisted of
a gonadotropin-releasing hormone agonist with an anti-
androgen. For the intermediate-risk patients, ADT was
administered for 6 months, during 3 months of which, it
was administered neoadjuvantly. For the high-risk pa-
tients, ADT was administered from the 6-month time
point to the 3-year time point, during 3 months of which,
it was administered neoadjuvantly. Six of the high-risk pa-
tients were combined with EBRT (Table 2).Treatment
Three to 7 days before implantation, patients underwent
a volumetric study of the prostate performed by transrectal
ultrasound (SONOLINE Adara SLC Ultrasound; Siemens,
Munich, Germany). Brachytherapy was performed in pa-
tients under epidural anesthesia. 125I seeds were accurately
introduced in preplanned positions by a brachytherapy
stepping unit (Computerized Medical System Inc., St.
Louis, MO) with a standard 0.5 cm brachytherapy template
placed over the perineum. 125I implants were generally pre-
scribed to 145 Gy for monotherapy and 110 Gy was
used in combination with EBRT. EBRT was delivered
with intensity-modulated radiation therapy.
The intraoperative planning time ranged from 20 to 35
minutes (mean 26 min), and the implantation time ranged
from 24 to 48 minutes (mean 31 min). Using real-time US
guidance, the radioactive seeds were then placed through
the needles with a Mick applicator. The implanted seeds
were of particle activity ranging from 0.30 mCi to 0.50
mCi each, with a total activity of 15 mCi to 43.2 mCi for
each patient, (mean 25.1 mCi). The D90 of monotherapy
ranged from 132 Gy to 170 Gy, and that of combination
therapy with EBRT ranged from 106 Gy to 113 Gy, with a
mean D90 of 142 Gy.
A KUB was scheduled after the procedure to check
the distribution of the implanted seeds. The urinary cath-
eter was withdrawn 1 to 3 days after the procedure. Four
to 6 weeks after the implantation, dosimetric analysis was
performed by computed tomography (CT). The D90 was
calculated in each patient.
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Figure 2 Overall survival rate for all cases was 90%.
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The patients were monitored based on serum PSA
measurement monthly during the first 3 months after
implantation and at 3-month intervals thereafter. If the
PSA level was stable, routine follow-up was scheduled
every 6 months for 2 years after the implantation. Compli-
cations were recorded. The endpoints of this study in-
cluded biochemical no evidence of disease (bNED) and
overall survival. Biochemical failure was determined using
the American Society of Radiation Oncology “Phoenix”
definition, based on the current nadir plus 2 ng/ml.
Genitourinary toxicities for hematuria, retention, and
incontinence and gastrointestinal toxicities were reported
using the Radiation Therapy Oncology Group (RTOG)/
European Organisation for Research and Treatment of
Cancer (EORTC) long-term toxicity scale.
Statistical analysis
Survival curves were generated using the Kaplan-Meier
method. Log-rank analysis was used for comparisons of
outcomes in various subgroups. Proportions were com-
pared with the use of chi-square tests. For all tests, a
value of p ≤ 0.05 was considered statistically significant.
Statistical analysis was performed using SPSS version
19.0 (SPSS Inc., Chicago, IL).
The enrolled patients consented to the study, which
was approved by the ethics research committee of the
Peking Union Medical College Hospital, Chinese Acad-
emy of Medical Science.
Results
With a mean follow-up of 84 months and a median
follow-up of 86 months (19–114 months), the nadir PSA
level ranged from 0 to 1.27 ng/ml (median 0.01 ng/ml).
Thirty-three patients had biochemical recurrence, pro-
ducing a bNED rate of 72% (Figure 1). Twelve patients
died, 4 of them from prostate cancer, for an overall sur-
vival rate of 90% (Figure 2) and a disease-specific survival
rate of 97%.
Among the 22 cases of low-risk prostate cancer, 3
experienced biochemical recurrence at 11 months, 48
months and 73 months after brachytherapy; the bNED
rate was 86%. No patient died, and the overall survival
rate was 100% for low-risk patients. Six of the 29 patients
with intermediate-risk disease had biochemical recurrence
at 7 months, 19 months, 30 months, 34 months, 37 months
and 60 months after the procedure; the bNED rate was
79%. Three deaths occurred because of lung cancer, myo-
cardial infarction and pancreatic cancer at 53 months, 95
months and 109 months after the procedure, producing
an overall survival rate of 90% among the intermediate-
risk patients. When combined, the low- and intermediate-
risk patients had a bNED rate of 82% and an overall survivalrate of 94%. Of the 66 high-risk patients, 24 biochemical
recurrences were observed between 7 and 70 months after
brachytherapy (16 occurred within a year). The bNED rate
of this group was 64%. Nine deaths occurred, 4 of which
were due to prostate cancer, at 41 months, 41 months, 86
months and 89 months after the procedure. The other 5
cases died from pancreatic cancer, lung cancer, cerebral
hemorrhage, pneumonia and renal failure at 19 months,
35 months, 56 months, 81 months and 101 months after
Table 3 bNED rate due to various factors
Factors N (bNED rate, %)
PSA
0-20.0 ng/ml 79 (59/76)











≥30 ml 74 (40/54)







≥140 Gy 81 (63/78)
<140 Gy 52 (17/33)
p-value 0.009
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group was 86%. EBRT and ADT were prescribed for pa-
tients who biochemically relapsed during the follow-up
period. The biochemical control results of the three sub-
groups were significantly different (P = 0.040) (Figure 3);
however, the overall survival rate of the three groups dem-
onstrated no significant difference (P = 0.189).
bNED was also examined among the different subgroups
(Table 3). Patients whose PPC was lower than 50% had a
lower biochemical recurrence likelihood than those whose
PPC was higher than 50% (P = 0.006) (Figure 4). Patients
who received a D90 higher than 140 Gy had better bio-
chemical control than those who received a D90 lower
than 140 Gy (P = 0.009) (Figure 5). Patients with a PSA
level lower than 20 ng/ml had a lower biochemical recur-
rence rate than those with a PSA level higher than 20 ng/ml
(P = 0.028). The bNED rate did not significantly differ be-
tween clinical stage T1b-T2b and T2c (P = 0.094). Add-
itionally, no significant differences in biochemical relapse
were observed in the subgroups with a Gleason score
higher or lower than 7 or the subgroups with a prostate
volume larger or smaller than 30 ml (P = 0.137, 0.104).
RTOG/EORTC graded genitourinary and gastrointes-
tinal toxicities were shown in Table 4. Urinary retention
was observed in 11 patients after brachytherapy (9.4%).
After urinary catheterization for 1 week, 10 patients
were cured. One patient was cured with transurethral
prostatectomy because of recurrent episodes of urinary
retention. Of the 62% (72/117) potent patients before
treatment, 67% (48/72) remained potent. No serious com-
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Figure 4 Patients whose PPC < 50% had less biochemical

















0 20 40 60 80 100 120
Time to Phoenix Failure (months)
D90 ≥ 140 Gy
D90 < 140 Gy
Figure 5 Patients whose D90 ≥ 140 Gy had better biochemical
control than those D90 < 140 Gy (P = 0.009).
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The radical effect of brachytherapy for localized prostate
cancer has been confirmed worldwide. Since the first
introduction of 125I brachytherapy from western countries
to China occurred more than a decade ago, few centers
have reported long-term outcomes. To our knowledge,
this is one of the largest cohort of prostate cancer patients
treated with brachytherapy with the longest follow-up
from mainland China reported to date, though the results
represent our early experience.
The indication for brachytherapy suggested by the
American Brachytherapy Society (ABS) is localized pros-
tate cancer (Nag et al. 1999; Davis et al. 2012). Brachyther-
apy monotherapy can achieve radical effects for localized
low-risk prostate cancer. However, for intermediate- and
high-risk patients, EBRT or ADT should be added. Al-
though patients may benefit from the combined therapy
in terms of overall survival rate, they also experienceTable 4 RTOG/EORTC graded genitourinary and
gastrointestinal toxicities
Toxicity Grage 0-1 Grade 2 Grade 3 Grade 4
Genitourinary
Retention 106 10 1 0
Hematuria 103 14 0 0
Incontinence 113 4 0 0
Gastrointestinal
Proctitis 109 6 2 0
Rectal bleeding 108 8 1 0increased economic burden, additional complications, and
greater inconvenience to their daily lives. For these rea-
sons, the latest ABS guidelines suggest that brachytherapy
monotherapy can also be applied in intermediate-risk lo-
calized prostate cancer (Davis et al. 2012). Although there
is solid evidence indicating that brachytherapy monother-
apy achieves the same curative effect as brachytherapy
combined with EBRT (Blasko et al. 2000), many clinical
centers have added ADT or EBRT routinely for intermediate-
risk localized prostate cancer patients (Davis et al. 2012).
In our study population, we prescribed 6 months of ADT
in intermediate-risk patients. We initially planned to add
EBRT for high-risk patients before or after brachytherapy.
However, due to the serious urinary track irritation and
rectal irritation symptoms associated with the first 6 pa-
tients and the relatively optimistic outcomes from other
clinics with high-risk patients treated with brachytherapy
monotherapy (Merrick et al. 2003; Marshall et al. 2014),
we did not perform EBRT in the high-risk patients and
opted for brachytherapy monotherapy instead.
Regarding the combination with ADT, we refer to the
experience of EBRT combined with ADT: long-term (2–
3 years) ADT can improve the biochemical relapse-free
survival rate and the overall survival rate of high-risk
prostate cancer (Bolla et al. 2009; Hanks et al. 2003). In
our study, all of the high-risk patients received ADT, 39
of whom underwent ADT for more than 2 years; ADT
in the other 27 cases was administered for less than 2
years for a variety of reasons. Marshall et al.’s study re-
ported that ADT had a benefit in reducing the biochem-
ical recurrence rate after brachytherapy (Marshall et al.
2014). However, Stock has stated that ADT improves
FBF only in the setting of lower doses, i.e., a biological
effective dose <220 Gy (Stock et al. 2013). The benefit of
ADT may primarily be as an enhancer of local control,
explaining why high radiation doses can compensate for
its absence. Therefore, we prescribed ADT for all high-
risk and intermediate-risk patients. Regarding the low-
risk patients, the neoadjuvant endocrine therapy was
aimed at reducing the volume of the prostate to reduce
the interference of the pubic arch.
For early stage prostate cancer, a radical effect can be
achieved with brachytherapy, EBRT, brachytherapy com-
bined with EBRT and radical prostatectomy (Davis et al.
2012; Aizer et al. 2009; Kupelian et al. 2004), with simi-
lar 5-year biochemical recurrence-free survival rates
(Kupelian et al. 2004). Patients can obtain a satisfactory
curative effect despite the risk category they fall in
(Marshall et al. 2014). Marshall et al.’s analyzed 2495 pa-
tients with localized prostate cancer. The 12-year bio-
chemical recurrence-free survival rate was 83% (90% for
the low-risk group, 84% for the intermediate-risk group
and 64% for the high-risk group). The cancer-specific
survival rate was 95%, and the overall survival rate was
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showed different clinical outcomes among different cen-
ters. The biochemical recurrence-free survival rate for
low-, intermediate- and high-risk patients 3 to 7 years
after brachytherapy ranged from 85%-96%, 74%-97%
and 38%-82%, respectively. With a 7-year follow-up, our
study population had an overall biochemical recurrence-
free survival rate of 72% (86%, 79% and 64% for the low-,
intermediate- and high-risk patients, respectively). The
cancer-specific survival rate was 97%, and the overall sur-
vival rate was 90%. Compared with previous studies, we
obtained similar results in the intermediate-risk patients
and relatively poor outcomes in the low-risk patients. We
believe the reasons for these findings are as follows. 1. The
study enrolled a relatively small study cohort. 2. The study
administered a low therapeutic radiation dose. Of the 111
patients in our cohort treated with brachytherapy alone,
33 cases had a D90 < 140 Gy, among which 17 patients
had biochemical relapse. The biochemical relapse rate was
higher in patients with a D90 < 140 Gy than in those with
a D90 ≥ 140 Gy, indicating that the therapeutic radiation
dose is related to the cure effect (Stone et al. 2005). 3. In
our center, the 125I seeds were implanted with a Mick ap-
plicator, rather than using a seed strand, thus resulting in
a relatively reduction of therapeutic radiation due to seed
migration (Lin et al. 2007). However, the seed strand
method has not yet been introduced to mainland China.
In general, the factors affecting the effect of brachy-
therapy can be divided into preoperative, operative and
postoperative. The preoperative factors are the PSA level
(Potters et al. 2008), Gleason score (Sylvester et al. 2011),
risk stratification (Taira et al. 2010), PPC (Taira et al.
2011) and prostate volume (Le et al. 2013). The operative
factors are therapeutic radiation dose (Stone et al. 2005)
and the proficiency of implantation (Zelefsky et al. 2007),
and the postoperative factor is combination with ADT
(Marshall et al. 2014) or EBRT (Davis et al. 2012). The re-
sults indicated that biochemical recurrence rates differ sig-
nificantly among groups of patients with different risk
factors, showing compliance with results from other cen-
ters. However, the overall survival rates among the three
groups were of not significantly different, most likely due
to our relatively small sample. Based on the analysis of the
risk factors, PSA ≥20 ng/ml, PPC ≥50%, and a D90 < 140
Gy were associated with a high biochemical recurrence
rate, as suggested by previous studies (Stone et al. 2005;
Potters et al. 2008; Taira et al. 2011). Interestingly, we dis-
covered that PPC had a more obvious relationship with
the biochemical relapse rate than other factors such as
clinical stage or risk stratification. Researchers have also
suggested that PPC, being an independent predictive fac-
tor, plays a significant role in predicting the biochemical
relapse-free survival rate and the overall survival rate in
patients undergoing radical prostatectomy (Briganti et al.2007), EBRT (Spalding et al. 2007) and brachytherapy
(Urani et al. 2007).
Urinary retention is the commonly observed compli-
cation after brachytherapy for prostate cancer. How-
ever, the majority of cases can be improved by urinary
catheterization combined with alpha blockers; only a few
require TURP intervention. TURP should be delayed 6
months after brachytherapy to avoid urinary incontinence.
One of the patients in our study population who had re-
peated recurrence of urinary retention underwent TURP,
with subsequent symptom improvement. Prostate rectal
fistula has a relatively low incidence, lower than 1%; how-
ever, with a difficult intervention, these cases often require
fecal and urinary diversion (Elebrezze & Medich 2003).
No prostate rectal fistula was observed in our patients be-
cause we were conservative about the radiation dose deliv-
ered to the prostate area adjacent to the rectum. The
reduced local radiation dose might inevitably have led to
relatively poorer treatment effect.
In conclusion, we believe that 125I brachytherapy for
prostate cancer is an effective, less traumatic method with
fewer complications than radical methods of prostate can-
cer treatment. Further randomized controlled studies with
larger samples from multiple centers are needed to verify
the efficacy and complications of this method in mainland
China.
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